Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been given a consensus rating of “Moderate Buy” by the five analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.3333.

Several equities analysts have issued reports on AUTL shares. Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Needham & Company LLC dropped their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th.

Autolus Therapeutics Trading Down 4.2%

Autolus Therapeutics stock opened at $1.38 on Tuesday. The stock has a 50 day moving average of $1.56 and a two-hundred day moving average of $1.73. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $2.70. The stock has a market capitalization of $367.27 million, a price-to-earnings ratio of -1.66 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The company had revenue of $21.19 million for the quarter, compared to analysts’ expectations of $21.08 million. Equities analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently modified their holdings of the business. Armistice Capital LLC boosted its holdings in Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after buying an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd lifted its position in shares of Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after acquiring an additional 900,000 shares during the period. Cetera Investment Advisers boosted its stake in shares of Autolus Therapeutics by 17.6% during the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after acquiring an additional 92,300 shares in the last quarter. Atle Fund Management AB boosted its stake in shares of Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after acquiring an additional 625,817 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Autolus Therapeutics in the 2nd quarter worth approximately $50,000. 72.83% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.